Moloney Securities Asset Management LLC Acquires 507 Shares of Illumina, Inc. (NASDAQ:ILMN)

Moloney Securities Asset Management LLC increased its position in Illumina, Inc. (NASDAQ:ILMN) by 33.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,032 shares of the life sciences company’s stock after purchasing an additional 507 shares during the period. Moloney Securities Asset Management LLC’s holdings in Illumina were worth $212,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Envestnet Portfolio Solutions Inc. boosted its stake in Illumina by 426.0% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 15,460 shares of the life sciences company’s stock worth $2,123,000 after purchasing an additional 12,521 shares in the last quarter. Findlay Park Partners LLP bought a new position in Illumina during the 1st quarter valued at about $100,120,000. Jupiter Asset Management Ltd. bought a new position in Illumina during the 1st quarter valued at about $4,527,000. Norges Bank bought a new position in Illumina during the 4th quarter valued at about $264,636,000. Finally, US Bancorp DE lifted its stake in Illumina by 33.9% during the 1st quarter. US Bancorp DE now owns 31,600 shares of the life sciences company’s stock valued at $4,339,000 after acquiring an additional 8,001 shares during the period. Institutional investors own 89.42% of the company’s stock.

Illumina Stock Performance

Illumina stock opened at $131.40 on Friday. The company’s 50-day moving average price is $118.81 and its 200-day moving average price is $121.84. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.26. The company has a market cap of $20.93 billion, a PE ratio of -16.12 and a beta of 1.15. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $171.50.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.24. The company had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The firm’s revenue for the quarter was down 5.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.32 earnings per share. On average, equities research analysts forecast that Illumina, Inc. will post 1.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ILMN shares. Stephens reaffirmed an “overweight” rating and set a $170.00 price target on shares of Illumina in a research report on Wednesday, July 10th. Piper Sandler reduced their price target on shares of Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a research report on Tuesday, August 13th. Evercore ISI reduced their price target on shares of Illumina from $195.00 to $175.00 and set an “outperform” rating for the company in a research report on Tuesday, June 11th. Jefferies Financial Group initiated coverage on shares of Illumina in a research note on Monday, June 3rd. They set a “hold” rating and a $115.00 target price on the stock. Finally, Scotiabank dropped their price target on shares of Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $151.05.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.